Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary: Sun Pharmaceutical Industries Limited** Sun Pharmaceutical faces maximum financial exposure through its critical compliance risk (10.0/10 score), with estimated remediation costs of ₹37–138 crore under SEBI BRSR Core Expansion mandates; non-compliance could trigger enforcement actions and delisting risk given the company's top-tier market status. The company's unknown EPR (Extended Producer Responsibility) applicability status presents a secondary exposure of 6.5/10, as pharmaceutical packaging obligations under India's Plastic Waste Management Rules could impose unquantified future liabilities depending on product classification and recovery target enforcement. Data gaps on Scope 1 and 2 emissions reporting—critical for BRSR P6 compliance—compound regulatory risk; at current India CCTS benchmarks (₹600–900/tonne), unaccounted emissions could translate into carbon credit deficits if mandatory carbon accounting becomes enforceable. Immediate priority: clarify EPR obligations, establish emissions baselines, and close BRSR disclosure gaps to mitigate delisting risk and the ₹37–138 crore compliance cost
Source: Sun Pharmaceutical Industries Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.